Fixed combination of repaglinide and metformin in the management of type 2 diabetes
Robert MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Treatment to target fasting blood glucose (FBG), postprandial glucose (PPG) and HbA1c are essential in the management of type 2 diabetes to reduce the risk of vascu...
Main Author: | Robert Moses |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-06-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/fixed-combination-of-repaglinide-and-metformin-in-the-management-of-ty-a3289 |
Similar Items
-
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
by: Robert G Moses
Published: (2010-05-01) -
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
by: Moses R
Published: (2010-05-01) -
Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
by: Xie J, et al.
Published: (2019-04-01) -
Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
by: Jonathan K Reynolds
Published: (2009-07-01) -
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
by: Fleming JW, et al.
Published: (2015-06-01)